Developer of a specialty chemicals platform designed to replace petroleum-based products with plant-derived substitutes.
Developer of a specialty chemicals platform designed to replace petroleum-based products with plant-derived substitutes.
Specialty Chemicals📍 Omaha, NEFounded 2022
Current Valuation
$2.2B
as of 2022-Q4
UNICORN
QL Price
$1.8B
-16% vs last round
QuantLogix's current estimate for Solugen, published 2026-09-14 — below the last disclosed round of $2.2B (2022-Q4).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$2.2B
2022-Q4
weight 0.08
Secondary market print
$1.8B
2026-06-27
weight 0.62
How this price has held up
No round has priced for Solugen since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-14 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Solugen, 2026-09-14 (080a8ccbff0eb909).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Solugen going public?
No. Solugen is private and has not filed to go public. There is no S-1 on file.
What is Solugen's valuation in 2026?
Solugen is valued at $2.2B as of 2022-Q4, set by its Series D ($200M, Oct 2022). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Solugen filed an S-1?
No public S-1 is on file for Solugen.
Can you buy Solugen stock?
No. Solugen is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Solugen on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2022
HQ
Omaha, NE
Employees
11
Total Raised
$640.45M
Last Round
Series D — $200M (Oct 2022)
IPO Status
private
Fundraising Status
Series D · $200M · 3y 11mo ago
privateTotal raised $640.45M
Secondary Market
Implied price / share
$33.46
Last round price / share
$40.7
vs last round
-17.8%
Open interest
2
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$200M
Oct 2022
—
$2.2B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Solugen — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-11. Re-checked weekly.
Talent Signal
No public careers page or job board could be found for Solugen as of 2026-08-17. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
GreenTechBiotechnologyChemicalBiopharmaOil and GasManufacturing
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2022-Q4. Refreshed quarterly.